Endothelin XII

Matthias Barton, Masashi Yanagisawa, Paul M. Vanhoutte, Tomoh Masaki

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Following the initial description of endothelium-dependent vasoconstriction in the early 1980s, it has been exactly 25 years since efforts to identify the sequence of the endothelin gene and peptide began in May 1987, work which resulted in a landmark paper submitted to Nature in December 1987 and published on March 31, 1988. The paper opened an entirely new field of research, followed by the inception of the International Conferences of Endothelin, the first of which was organized by Sir John Vane as Chair and held as the First William Harvey Workshop on Endothelin in London, UK, in December of 1988. Endothelin receptor antagonism has now been firmly established for more than a decade as a new, orally active drug treatment for patients with pulmonary arterial hypertension. Since the discovery of endothelin, on average 1,000 papers per year have been published with more than 25,000 papers available today, many of them published in the conferences' Proceedings. The present issue of Life Sciences, Endothelin XII, represents a collection of papers of original research and invited lectures presented at the Twelfth International Conference on Endothelin held in Cambridge, UK, in September 2011.

Original languageEnglish (US)
Pages (from-to)449-451
Number of pages3
JournalLife Sciences
Volume91
Issue number13-14
DOIs
StatePublished - Oct 15 2012

Fingerprint

Endothelins
Drug therapy
Endothelin Receptors
Biological Science Disciplines
Vasoconstriction
Research
Pulmonary Hypertension
Endothelium
Genes
Education
Peptides
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Pharmacology, Toxicology and Pharmaceutics(all)
  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Barton, M., Yanagisawa, M., Vanhoutte, P. M., & Masaki, T. (2012). Endothelin XII. Life Sciences, 91(13-14), 449-451. https://doi.org/10.1016/j.lfs.2012.07.016

Endothelin XII. / Barton, Matthias; Yanagisawa, Masashi; Vanhoutte, Paul M.; Masaki, Tomoh.

In: Life Sciences, Vol. 91, No. 13-14, 15.10.2012, p. 449-451.

Research output: Contribution to journalArticle

Barton, M, Yanagisawa, M, Vanhoutte, PM & Masaki, T 2012, 'Endothelin XII', Life Sciences, vol. 91, no. 13-14, pp. 449-451. https://doi.org/10.1016/j.lfs.2012.07.016
Barton M, Yanagisawa M, Vanhoutte PM, Masaki T. Endothelin XII. Life Sciences. 2012 Oct 15;91(13-14):449-451. https://doi.org/10.1016/j.lfs.2012.07.016
Barton, Matthias ; Yanagisawa, Masashi ; Vanhoutte, Paul M. ; Masaki, Tomoh. / Endothelin XII. In: Life Sciences. 2012 ; Vol. 91, No. 13-14. pp. 449-451.
@article{118cf9c0cd4a4019a22699885419a34b,
title = "Endothelin XII",
abstract = "Following the initial description of endothelium-dependent vasoconstriction in the early 1980s, it has been exactly 25 years since efforts to identify the sequence of the endothelin gene and peptide began in May 1987, work which resulted in a landmark paper submitted to Nature in December 1987 and published on March 31, 1988. The paper opened an entirely new field of research, followed by the inception of the International Conferences of Endothelin, the first of which was organized by Sir John Vane as Chair and held as the First William Harvey Workshop on Endothelin in London, UK, in December of 1988. Endothelin receptor antagonism has now been firmly established for more than a decade as a new, orally active drug treatment for patients with pulmonary arterial hypertension. Since the discovery of endothelin, on average 1,000 papers per year have been published with more than 25,000 papers available today, many of them published in the conferences' Proceedings. The present issue of Life Sciences, Endothelin XII, represents a collection of papers of original research and invited lectures presented at the Twelfth International Conference on Endothelin held in Cambridge, UK, in September 2011.",
author = "Matthias Barton and Masashi Yanagisawa and Vanhoutte, {Paul M.} and Tomoh Masaki",
year = "2012",
month = "10",
day = "15",
doi = "10.1016/j.lfs.2012.07.016",
language = "English (US)",
volume = "91",
pages = "449--451",
journal = "Life Sciences",
issn = "0024-3205",
publisher = "Elsevier Inc.",
number = "13-14",

}

TY - JOUR

T1 - Endothelin XII

AU - Barton, Matthias

AU - Yanagisawa, Masashi

AU - Vanhoutte, Paul M.

AU - Masaki, Tomoh

PY - 2012/10/15

Y1 - 2012/10/15

N2 - Following the initial description of endothelium-dependent vasoconstriction in the early 1980s, it has been exactly 25 years since efforts to identify the sequence of the endothelin gene and peptide began in May 1987, work which resulted in a landmark paper submitted to Nature in December 1987 and published on March 31, 1988. The paper opened an entirely new field of research, followed by the inception of the International Conferences of Endothelin, the first of which was organized by Sir John Vane as Chair and held as the First William Harvey Workshop on Endothelin in London, UK, in December of 1988. Endothelin receptor antagonism has now been firmly established for more than a decade as a new, orally active drug treatment for patients with pulmonary arterial hypertension. Since the discovery of endothelin, on average 1,000 papers per year have been published with more than 25,000 papers available today, many of them published in the conferences' Proceedings. The present issue of Life Sciences, Endothelin XII, represents a collection of papers of original research and invited lectures presented at the Twelfth International Conference on Endothelin held in Cambridge, UK, in September 2011.

AB - Following the initial description of endothelium-dependent vasoconstriction in the early 1980s, it has been exactly 25 years since efforts to identify the sequence of the endothelin gene and peptide began in May 1987, work which resulted in a landmark paper submitted to Nature in December 1987 and published on March 31, 1988. The paper opened an entirely new field of research, followed by the inception of the International Conferences of Endothelin, the first of which was organized by Sir John Vane as Chair and held as the First William Harvey Workshop on Endothelin in London, UK, in December of 1988. Endothelin receptor antagonism has now been firmly established for more than a decade as a new, orally active drug treatment for patients with pulmonary arterial hypertension. Since the discovery of endothelin, on average 1,000 papers per year have been published with more than 25,000 papers available today, many of them published in the conferences' Proceedings. The present issue of Life Sciences, Endothelin XII, represents a collection of papers of original research and invited lectures presented at the Twelfth International Conference on Endothelin held in Cambridge, UK, in September 2011.

UR - http://www.scopus.com/inward/record.url?scp=84867574708&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84867574708&partnerID=8YFLogxK

U2 - 10.1016/j.lfs.2012.07.016

DO - 10.1016/j.lfs.2012.07.016

M3 - Article

C2 - 22842029

AN - SCOPUS:84867574708

VL - 91

SP - 449

EP - 451

JO - Life Sciences

JF - Life Sciences

SN - 0024-3205

IS - 13-14

ER -